Evommune Halts EVO756 in Atopic Dermatitis After Phase 2b Failure; Pivots to Migraine
EVMN is trading near its 52-week low of $10.47 (4.0% above the low).
Summary
Evommune's EVO756 missed all endpoints in a 121-patient Phase 2b atopic dermatitis trial, prompting the company to halt AD development and pivot to migraine. EVO301 becomes the lead AD program, with cash runway extended into 2029.
Key Events · Product Development and Regulatory · EVMN
-
EVO756 Phase 2b AD Trial Fails
The 121-patient Phase 2b trial in moderate-to-severe atopic dermatitis missed primary and secondary endpoints in all doses studied.
-
AD Development Ceased for EVO756
Based on the results, Evommune will not advance EVO756 in atopic dermatitis, marking the second major pipeline setback in three months after the June 2026 CSU failure.
-
Pivot to Migraine Prophylaxis
EVO756 will continue in a Phase 2b trial for migraine prophylaxis, with the company citing a generally well-tolerated safety profile.
-
EVO301 Becomes Lead AD Program
EVO301, an IL-18BP fusion protein with positive Phase 2a proof-of-concept data, will enter a Phase 2b trial planned for mid-2027.
Analysis · EVMN · Life Sciences
Evommune's lead oral candidate EVO756 failed its Phase 2b atopic dermatitis trial, missing primary and secondary endpoints across all doses. The company is ceasing AD development for EVO756 and pivoting to migraine prophylaxis, while EVO301 becomes the lead AD program with a Phase 2b planned for mid-2027. The cash runway extends into 2029, providing a buffer, but the stock is trading near its 52-week low after this second major pipeline setback in three months.
How filings like this one have moved
In the 30 days to Sep 12, 2026, 35.9% of the 1612 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.19%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, EVMN was trading at $10.89 on NYSE in the Life Sciences sector, with a market capitalization of approximately $474.7M. The 52-week trading range was $10.47 to $33.20. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.